MTOR and Hodgkins lymphoma: In summary, the morphoproteomic/morphometric findings in this “unusual responder” patient's relapsed HL that correlate best – as a response signature with the subsequent clinical remission following rapamycin (sirolimus) and vorinostat (SAHA) therapies – center on an immune dysregulation involving an imbalance between effector and functional T regulatory cells in addition to targeting the mTOR pathway.